Karel Petrak

An executive with 25 years experience in pharmaceutical industry, with demonstrated success in pharmaceutical and biotechnology drug development, drug discovery and delivery of conventional drugs, proteins, and peptides. Versed in regulatory requirements and interactions with the FDA and other regulatory agencies. Recognized for establishing a solid base of NIH SBIR funding.
PROFESSIONAL EXPERIENCE

AGENNIX, INC. – Houston, Texas 2000 – 2010
Start-up biopharmaceutical company developing recombinant human lactoferrin (talactoferrin) to treat cancer, severe sepsis, and neonatal nosocomial infections.
Vice President, Research and Development
Responsible for pre-clinical activities to identify new therapeutic indications (oncology, wound healing, sepsis, asthma, infections, inflammation) for the company’s proprietary compounds. Co-authored several patents that resulted from this.
Drafted, submitted, and obtained funding for several NIH SBIR and STTR Phase I and Phase II Grants.